Information Sinopharm Jiangsu Co., Ltd
It was established in 1998 and jointly established by the Jiangsu Provincial Medicine Administration, China Pharmaceutical Foreign Trade Corporation and Nanjing Hanhe Industrial Co.,
Information Sinopharm Group Company Limited
The Group provides distribution, logistics and other value-added services for pharmaceutical and healthcare products of domestic and international manufacturers and other suppliers.
Information Sinopharm (company)
China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise.
Information Sinopharm Group
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China
Information Sinopharm Group Co. Ltd.
The pharmaceutical distribution business continuously consolidated its leading advantages with its terminal network covering more than 700,000 customers in various provinces (autonomous regions,
Information CHINA SINOPHARM INTERNATIONAL CORPORATION
Leveraging the advantages of international trade, it initiates an all-rounded business model, covering downtown, border, airport, port, offshore, overseas and online, and strives to create a duty-free
Information Supply Chain Services--
Sinopharm Foreign Trade boasts a pharmaceutical logistics center and a medical device logistics center near the airport area.
Information Sinopharm
China National Pharmaceutical Group Co Ltd (Sinopharm) has enterprises such as China National Pharmaceutical Investment Co Ltd, one of its wholly-owned subsidiaries, dedicated to high-end
Information intelligent distribution cabinet Manufacturers and Suppliers
Our company has a quality assurance system have been established for intelligent distribution cabinet, intelligent power distribution cabinet, distribution cabinet, power distribution cabinet, smart
Information 2023Annual Report
During the Reporting Period, the Group recorded a revenue of RMB596,569.57 million, representing an increase of 8.05% as compared with RMB552,147.55 million for the twelve months ended 31